Biopolym. Cell. 1999; 15(3):179-194.
http://dx.doi.org/10.7124/bc.000517
Огляди
Особливості розповсюдження ВІЛ-інфекції в Україні та передумови для нового витка еволюції етіологічного фактора СНІДу
1Кордюм В. А.
  1. Інститут молекулярної біології і генетики НАН України
    Вул. Академіка Заболотного, 150, Київ, Україна, 03680

Abstract

Населення України, за станом, імунної системи можна умовно поділити на декілька рівнів. Це так звані "здорові" люди, у яких вже спостерігаються клінічні зрушення імунітету, – І рівень; популяція населення особливо екологічно забрудненого Донецько-Придніпровського промислового району та півдня країни – II рівень та III – група, що недавно сформувалася, з ін'єкційних наркоманів (як правило, серед населення з ІІ рівнем), із яких особливо вирізняються такі, що споживають специфічні для України наркотики на основі ефедрину. Саме ця остання популяція населення із зниженим імунним статусам (ін'єкційні наркомани особливо екологічно забдруднених районів) е сприятливим середовищем для еволюції та подальшого розповсюдження вірусу імунодефіциту. Циркулюючи в цьому середовищі, додатково змінившись та набувши нових властивостей, вірус надалі може бути здатним уражати людей з менш порушеною імунною системою, охоплюючи при цьому все ширші кола населення.
Повний текст: (PDF, російською)

References

[1] WHO-bericht Nr. 15 zur AIDS-Verbreitung in Europa (Stand: 30 September 1987). AIDS-Forsch. 1988. 3(3):168—175.
[2] Lukashov VV, Cornelissen MT, Goudsmit J, Papuashvilli MN, Rytik PG, Khaitov RM, Karamov EV, de Wolf F. Simultaneous introduction of distinct HIV-1 subtypes into different risk groups in Russia, Byelorussia and Lithuania. AIDS. 1995;9(5):435-9.
[3] Gol'chinkiy A. Revitalize principles the Union economy - then again fall into the trap of illusion. Newspaper Vseukrainskie Vedomosti 5 June 1996.
[4] McMare-Canac V. Et Ie SIGA, docteur? Tempo med. 1965. N 205:29—30; 32-34; 37-38.
[5] MacGregor RR. Alcohol and drugs as co-factors for AIDS. Adv Alcohol Subst Abuse. 1987;7(2):47-71.
[6] Peterson PK, Gekker G, Chao CC, Schut R, Molitor TW, Balfour HH Jr. Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures. Involvement of transforming growth factor-beta. J Immunol. 1991;146(1):81-4.
[7] Frolov VM, Peresadin NA, Kazakova SE, Safonov EF State of immunity in patients with neuropsychological disorders who participated in the aftermath of the Chernobyl accident and the effectiveness of immune. Immunology. 1993; 3:55-61.
[8] Nahmias AJ, Weiss J, Yao X, Lee F, Kodsi R, Schanfield M, Matthews T, Bolognesi D, Durack D, Motulsky A, et al. Evidence for human infection with an HTLV III/LAV-like virus in Central Africa, 1959. Lancet. 1986;1(8492):1279-80.
[9] Norman C. Africa and the origin of AIDS. Science. 1985;230(4730):1141.
[10] Koiek R. Das-Undenkbare-denken. Die Entsteliurigs geschichte von AIDS. Wecbselwirkung. 1988; 10(36):34—37.
[11] Smith TF, Srinivasan A, Schochetman G, Marcus M, Myers G. The phylogenetic history of immunodeficiency viruses. Nature. 1988;333(6173):573-5.
[12] Sonnet J, Michaux JL, Zech F, Brucher JM, de Bruyere M, Burtonboy G. Early AIDS cases originating from Zaire and Burundi (1962-1976). Scand J Infect Dis. 1987;19(5):511-7.
[13] Bergstrom T, Biberfeldt G, Bottiger B, Hakansson C, Hellstrand K, Hermodsson S, Norkrans G, Strannegard O, Thoren K. Impaired production of alpha and gamma interferon in asymptomatic homosexual males. Eur J Clin Microbiol. 1986;5(5):523-9.
[14] Afrika: HTLV-III-Antikorper bereits 1959 nachweisbar. AIDS-Forech. 1986; 1(9):482—483.
[15] Letevre Chr. Adam etait-il seropositif? Sci et vie. 1990. 174:50—55.
[16] Sansone R, Carobbi S, Alloro G, Strigini P. AIDS in Africa. Ann Ig. 1989;1(5):1057-66.
[17] Getchell JP, Hicks DR, Svinivasan A, Heath JL, York DA, Malonga M, Forthal DN, Mann JM, McCormick JB. Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa. J Infect Dis. 1987;156(5):833-7.
[18] Zhang YJ, Putkonen P, Albert J, Ohman P, Biberfeld G, Fenyo EM. Stable biological and antigenic characteristics of HIV-2SBL6669 in nonpathogenic infection of macaques. Virology. 1994;200(2):583-9.
[19] Brown F. "Earlist" AIDS case offer to virus. New Sci. 1990; 127(1725):34.
[20] Les annees Sida. Un entretien avec Jonathan Mann J. Int. Med. 1987. N 87:177—1178; 181; 183; 185; 187; 189; 191—192.
[21] Adier M W. AIDS an introduction. Med. Int. (Gr. Brit.). 1988; 56:2326—2330.
[22] Cougoir J. Immunocentered HIV co-factors of AIDS. AIDS. 1987; 1(7):304—305
[23] Li WH, Tanimwa M, Sharp PM. Rateii and dates of divergence between AIDS virus nucleotide sequences. Genetics. 1987. 116(1 Pt 2, Suppl):44
[24] Penny D. Origins of the AIDS virus. Nature. 1988;333(6173):494-5.
[25] SIDA: variabilite genetique du virus et progression de l'epidemie. M/s: Med. sci. 1986. 2(8):461.
[26] Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science. 1988;242(4882):1171-3.
[27] Bronson EC, Anderson JN. Nucleotide composition as a driving force in the evolution of retroviruses. J Mol Evol. 1994;38(5):506-32.
[28] Hu WS, Temin HM. Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidy and high rate of genetic recombination. Proc Natl Acad Sci U S A. 1990;87(4):1556-60.
[29] Dunois B. Manipulations genetiques: Apocalypse-virus. J. Int. Med. 1990; 163:15—16.
[30] Des mutants virulents et hypervirulents de virus de Pimmunodeficience simienne (SIV). M/s.: Med. sci. 1990; 6(7):693.
[31] Adachi A, Koenig S, Gendelman HE, Daugherty D, Gattoni-Celli S, Fauci AS, Martin MA. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol. 1987;61(1):209-13.
[32] Rectal/colon cells: AIDS incubatos? Bioeng. News. 1987. 8(3):2.
[33] Baum RM. AIDS researchers make inroads in understanding a complex virus. Chem. Eng. News. 1986; 64(48):7—12.
[34] Proffitt MR, Ven-Lieberman B, Hobbs R. et al Isolation of HIV (HTLV-III/LAV) from the heart muscle of a patient with AIDS-related complex (ARS) and cardiomyopathy: Abstr. Annu. Meet. (Atlanta, Ga, 1—6 March, 1987). Washington: D. S., 1987;329.
[35] Pomerantz RJ, Kuritzkes DR, de la Monte SM, Rota TR, Baker AS, Albert D, Bor DH, Feldman EL, Schooley RT, Hirsch MS. Infection of the retina by human immunodeficiency virus type I. N Engl J Med. 1987;317(26):1643-7.
[36] Donaldson Y., Holmes E. C., Rebus S. et aL Variation in HIV: 167th Meet. Pathol. Soc. G. Brit, and Irel. (Edinburgh, 7—9 July, 1993). J Med Microbiol. 1993; 39(Suppl., l):8.
[37] Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA. 1986;83(18):7089-93.
[38] Funke I, Hahn A, Rieber EP, Weiss E, Riethmüller G. The cellular receptor (CD4) of the human immunodeficiency virus is expressed on neurons and glial cells in human brain. J Exp Med. 1987;165(4):1230-5.
[39] Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science. 1987;236(4803):819-22.
[40] Agostini C, Trentin L, Zambello R, Semenzato G. HIV-1 and the lung. Infectivity, pathogenic mechanisms, and cellular immune responses taking place in the lower respiratory tract. Am Rev Respir Dis. 1993;147(4):1038-49.
[41] Clarke JR, Coker RJ, Harris JR, Mitchell DM. Rapidly evolving HIV-1 infection in lung of AIDS patient. Lancet. 1994;344(8923):679-80.
[42] Angelique VWB, Ran LJ, Koorstra VA. et al. Analysis of the temporal relationship between human ummynodeficiency virus type I quasispecies in sequential blood samples and various organs obtained at autopsy: Abstr. Vancouver, 1996; 2:278.
[43] Luis SR, Renjito B, Martin KR. et al. Differential growth of HIV-I subtypes in Langerhans' cells, relation to transmission route: Abstr. Vancouver, 1996. Vol. 1. Tu. A. 2,074.
[44] Cohen J. Differences in HIV strains may underlie disease patterns. Science. 1995;270(5233):30-1.
[45] Assoziation von HIV-Infektion und Tuberkulose. AIDS-Foisch. 1987; 2(5):254.
[46] Le Joelie M. SIDA: peut-on sauver l'Afrique? J Int Med. 1992; 256:13—16.
[47] Brown Ph. New tuberculosis risk. World AIDS. 1992; 21:10.
[48] Pohle HD. Opportuiiistische infekflonen bei AIDS. Sitziirgsbiir Ges. Naturforssch Frunde Berlin. 1990. 29—30:119—124.
[49] Gilks CF. The clinical challenge of the HIV epidemic in the developing world. Lancet. 1993;342(8878):1037-9.
[50] O'Doherty MJ, Page CJ, Bradbeer CS, Shahmanesh M, Edwards A, Barlow D, Bateman NT, Croft DN. Alveolar permeability in HIV antibody positive patients with Pneumocystis carinii pneumonia. Genitourin Med. 1987;63(4):268-70.
[51] Perna F, De Masi AL, Bianchino G. et al. Interessamento poimonare In corso di AIDS. Arch. Monaldi fisiol. e malat. appor. respir. 1985; 40(3—4):165-186.
[52] Alness-lavrence C, Sanchez G, Le Contel C. et al. HIV-I replication in epithelial intestinal cells: Abstr. Vancouver, 1996. Vol. I:217; Tu. A. 142.
[53] Ekiiert W. Uberlleberasfrage: wie macht das AIDSA — virus AIDS?. Med. aktuell. 1992. 18, N 12:14; 16—18.
[54] Ezzell C. Hospital workers have AIDS virus. Nature. 1987;327(6120):261.
[55] Jecker NS. The responsibility to treat AIDS patients. AIDS Patient Care. 1990; 4(1):2—4.
[56] Koch MGY. Internationale AIDS-Konfereiiz in Montreal, 4—9 June 1989. AIDS-Forsch. 1990; 5(6):304—316.
[57] AIDS protection rules set for health workers. Chem and Engl New. 1991; 69(49):6.
[58] Leads from the MMWR. AIDS and HIV update: acquired immunodeficiency syndrome and human immunodeficiency virus infection among health-care workers. JAMA. 1988;259(19):2817-8, 2821.
[59] Isfort R, Jones D, Kost R, Witter R, Kung HJ. Retrovirus insertion into herpesvirus in vitro and in vivo. Proc Natl Acad Sci USA. 1992;89(3):991-5.
[60] Cell killing by AIDS virus. Science. 1988; 242(4885):1487.
[61] Brown P DNA test finds HTV's Hideout. New Sci. 1993. 138(1874):17.
[62] Goodrich DW, Duesberg PH. Retroviral recombination during reverse transcription. Proc Natl Acad Sci U S A. 1990;87(6):2052-6.
[63] Hirschman SZ, Zucker ML. Recombinant DNA related to hepatitis B and human immunodeficiency viruses in mononuclear cells of patients with AIDS. J Med Virol. 1988;26(2):145-52.
[64] SIDA: nouvelles menaces, nouveaux espoirs. Sci. et avenir. 1988; 497:76—80.
[65] Ablashi DV, Sturzenegger S, Hunter EA, Palestine AG, Fujikawa LS, Kim MK, Nussenblatt RB, Markham PD, Salahuddin SZ. Presence of HTLV-III in tears and cells from the eyes of AIDS patients. J Exp Pathol. 1987;3(4):693-703.
[66] Ho DD, Byington RE, Schooley RT, Flynn T, Rota TR, Hirsch MS. Infrequency of isolation of HTLV-III virus from saliva in AIDS. N Engl J Med. 1985;313(25):1606.
[67] Levy JA, Greenspan D. HIV in saliva. Lancet. 1988;2(8622):1248.
[68] Enzensberger W, Fischer P-A. Primare HIV-Kmplikationen des Nervensystems. AIDS-Forsch. 1987; 2(11):603—614.
[69] Kay LA. Immunology of human skin and susceptibility to HIV infection. Lancet. 1987;2(8551):166.
[70] Scheiermann N, Marcus I. HIV und AIDS: Risiken fur den Arzt und seine Mitarbeiter. MTA. 1987; 2(11):883—884
[71] Horton R. Renewed US AIDS strategy. Lancet. 1993;342(8885):1478.
[72] Lean GK, Salminen MO, Leinikki P. et al First full length sequence prototypes of HIV-I Cla des C, E and G: two of three are mosaic genomes: Abstr. Vancouver, 1996; 1:216.
[73] McCuthan FE, Salminen MO, Carr JK et al. Breakpoints in the full-length genomes of intergenotypic recombinants of HIV-I and their functional implications. Abstr. Vancouver, 1996. 1:278—279.
[74] Cheng-Mayer C, Tateno M, Seto D, Levy JA. Distinguishing features of neurotropic human immunodeficiency viruses. Vacciners'88: New Chem. and Genet. Approaches Vaccinat.: Prev. AIDS and Other Viral, Bact., and Parasit. Diseases: Conf. (Cold Spring Harbor, New York, Sept. 9, 1987). New York: Cold Spring Harbor Lab. publ., 1988:259—263.
[75] Ruscalleda J. Infections of central nervous system and AIDS general overview. Riv. nevroradiol. 1990; 3(2 Suppl):109—113.
[76] Kenneth RE, Jaffe HW, Schable CA. et al. XI International conference on AIDS: Abstrs. Vancouver, 1996. 1:216.